Program
penpulimab
Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.
Drug pagePenpulimab: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceuticalits history only | 187 open or running | phase 3since Apr 10, 2020 | Dec 17, 2019 | Dec 2026phase 3 · NCT04344158 |
| Akesoits history only | 92 open or running | phase 3since Mar 6, 2019 | Nov 21, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Nov 21, 2017.
- Jun 9, 2020Named penpulimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AK105
- Jul 13, 2021Phase 3 study in Nasopharyngeal CarcinomaAkeso · NCT04974398 · 296 enrolled · United States, Australia, Brazil and more
- Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerSino Biopharmaceutical · NCT05068206 · 120 enrolled · China
- Jan 25, 2022Phase 3 study in Hodgkin Disease LymphomaAkeso · NCT05244642 · 60 planned · China
- Apr 12, 2022Phase 1 study in Advanced CancersSino Biopharmaceutical · NCT05333276 · 7 enrolled · China
- May 16, 2022Phase 2 study in LymphomaSino Biopharmaceutical · NCT05400876 · 92 enrolled · China
- Sep 27, 2022Phase 2 study in Nasopharyngeal CarcinomaSino Biopharmaceutical · NCT05563480 · 47 enrolled · China
- Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaSino Biopharmaceutical · NCT05834543 · 34 enrolled · China
- May 15, 2023Phase 3 study in Carcinoma, HepatocellularSino Biopharmaceutical · NCT05862337 · 480 planned · China
- May 31, 2023Phase 1 study in Advanced CancerSino Biopharmaceutical · NCT05894421 · 92 planned · China
- Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaSino Biopharmaceutical · NCT05975645 · 29 enrolled · China
- Mar 1, 20242 phase 1 studiesSino Biopharmaceutical · NCT06297642, NCT06320080
- Jul 8, 2024Phase 2 study in SarcomaSino Biopharmaceutical · NCT06500091 · 54 planned · China
- Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaSino Biopharmaceutical · NCT06767800 · 204 planned · China
- Feb 9, 2025Phase 2 study in Advanced Solid TumorSino Biopharmaceutical · NCT06825494 · 194 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Sino Biopharmaceutical · NCT04344158
TargetBeta
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Sino Biopharmaceutical | Mar 2026 | 194 |
| NCT06767800Gastroesophageal Adenocarcinoma · China | 2 | Recruiting | Sino Biopharmaceutical | Sep 2026 | 204 |
| NCT06500091Sarcoma · China | 2 | Not yet recruiting | Sino Biopharmaceutical | Jun 2026 | 54 |
| NCT06320080Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Sino Biopharmaceutical | Nov 3, 2025 | 22 |
| NCT06297642Advanced Malignant Neoplasm · China | 1 | Terminated | Sino Biopharmaceutical | Jul 31, 2024 | 3 |
| NCT05975645Advanced Hepatocellular Carcinoma · China | 1 | Terminated | Sino Biopharmaceutical | Jun 4, 2025 | 29 |
| NCT05894421Advanced Cancer · China | 1 | Recruiting | Sino Biopharmaceutical | Jan 2025 | 92 |
| NCT05862337Carcinoma, Hepatocellular · China | 3 | Recruiting | Sino Biopharmaceutical | Aug 2024 | 480 |
| NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | Sino Biopharmaceutical | Oct 23, 2024 | 34 |
| NCT05563480Nasopharyngeal Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | May 28, 2025 | 47 |
| NCT05400876Lymphoma · China | 2 | UNKNOWN | Sino Biopharmaceutical | May 2023 | 92 |
| NCT05333276Advanced Cancers · China | 1 | Active, not recruiting | Sino Biopharmaceutical | Dec 2023 | 7 |
| NCT05244642Hodgkin Disease Lymphoma · China | 3 | Recruiting | Akeso | Dec 30, 2025 | 60 |
| NCT05068206Unresectable Metastatic Colorectal Cancer · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2023 | 120 |
| NCT04974398Nasopharyngeal Carcinoma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Akeso | Feb 23, 2026 | 296 |
| NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Oct 31, 2023 | 528 |
| NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Active, not recruiting | Sino Biopharmaceutical | Dec 2026 | 648 |
| NCT04291248MSI-H or dMMR Advanced Solid Tumors · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 138 |
| NCT04207463Digestive System Neoplasms · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 150 |
| NCT04203719Advanced Head, Neck and Chest Cancer · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 140 |
| NCT04172571Carcinoma, Hepatocellular · China | 2 | Completed | Akeso | Jun 1, 2022 | 31 |
| NCT04172506Lung Neoplasms · China | 2 | Completed | Akeso | Dec 1, 2021 | 65 |
| NCT03866993Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Akeso | Oct 8, 2020 | 350 |
| NCT03866980Carcinoma, Non-Small-Cell Lung · China | 3 | Terminated | Akeso | Jun 30, 2023 | 164 |
| NCT03866967Nasopharyngeal Carcinoma · China | 2 | Completed | Akeso | Mar 13, 2021 | 130 |
| NCT03722147Hodgkin Disease · China | 2 | Completed | Akeso | Jan 10, 2020 | 94 |
| NCT03352531Advanced Cancer · Australia | 1 | Completed | Akeso | Nov 30, 2020 | 99 |
How it is read
Names in the registry
- “AK105”, 9 entries
- “Penpulimab”, 3 entries
- “Penpulimab injection”, 2 entries
- “AK105 injection”, 2 entries
- “TQB2618 injection; Penpulimab injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 5 studies
- Nasopharyngeal Carcinoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Hodgkin Disease, 2 studies
- Esophageal Squamous Cell Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.